Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P61278 (
somatostatin
)
22,083
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The gene encoding a novel mouse somatostatin receptor termed mSSTR3 was isolated and characterized. The sequence of mSSTR3 shows 46 and 47% identity with mSSTR1 and mSSTR2, respectively. mSSTR3 binds somatostatin-14 and somatostatin-28 with high affinity, but shows very low affinity for the
somatostatin
analogs MK-678 and SMS-201-995. In addition, mSSTR3 is coupled to pertussis toxin-sensitive G proteins and mediates
somatostatin
inhibition of forskolin-stimulated and dopamine D1 receptor-stimulated cAMP formation, indicating that it is coupled to adenylylcyclase. The pharmacological properties of mSSTR3 and its ability to couple with adenylylcyclase distinguish SSTR3 from the other cloned
somatostatin
receptors and indicates that it mediates biological functions different from
SSTR1
or SSTR2. In situ hybridization indicates that SSTR3 mRNA is widely distributed in the mouse brain, and its expression in the nucleus of the lateral olfactory tract and in the piriform cortex, the primary olfactory cortex in the rodent brain, suggests that SSTR3 may participate in the processing and modulation of primary sensory information.
...
PMID:Cloning of a novel somatostatin receptor, SSTR3, coupled to adenylylcyclase. 132 99
We previously reported the cloning of two distinct somatostatin receptor (SSTR) subtypes,
SSTR1
and SSTR2. Although both
SSTR1
and SSTR2 bound
somatostatin
specifically and with high affinity, neither was coupled to adenylyl cyclase, a major cellular effector of
somatostatin
's actions. Here we report the cloning and functional characterization of a third member of the SSTR family. Human SSTR3 is a protein of 418 amino acids and has 45% and 46% identity with human
SSTR1
and SSTR2, respectively. RNA blotting studies showed that SSTR3 mRNA could be readily detected in brain and pancreatic islets. The pharmacological properties of human SSTR3 were characterized by transiently expressing the human SSTR3 gene in COS-1 cells. Membranes from cells expressing human SSTR3 bound the
somatostatin
agonist [125I]CGP 23996 specifically and with high affinity, with a rank order of potency of somatostatin-28 = CGP 23996 > somatostatin-14 > SMS-201-995. Studies using cells transiently coexpressing the human dopamine D1 receptor and human SSTR3 showed that
somatostatin
was able to inhibit dopamine-stimulated cAMP formation in a dose-dependent manner, indicating that SSTR3 was functionally coupled to adenylyl cyclase. These results indicate that the diverse biological effects of
somatostatin
are mediated by a family of receptor with distinct, but overlapping, tissue distributions, unique pharmacological properties, and potentially different functions.
...
PMID:Somatostatin receptors, an expanding gene family: cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase. 133 45
Somatostatin
is a tetradecapeptide that is widely distributed in the body. It acts on multiple organs including brain, pituitary, gut, exocrine and endocrine pancreas, adrenals, thyroid, and kidneys to inhibit release of many hormones and other secretory proteins. In addition, it functions as a neuropeptide affecting the electrical activity of neurons.
Somatostatin
exerts its biological effects by binding to specific high-affinity receptors, which appear in many cases to be coupled to GTP-binding proteins. Here we report the cloning, functional expression, and tissue distribution of two different
somatostatin
receptors (SSTRs).
SSTR1
and SSTR2 contain 391 and 369 amino acids, respectively, and are members of the superfamily of receptors having seven transmembrane segments. There is 46% identity and 70% similarity between the amino acid sequences of
SSTR1
and SSTR2. Stably transfected Chinese hamster ovary cells expressing
SSTR1
or SSTR2 exhibit specific
somatostatin
binding, with an apparently higher affinity for somatostatin-14 than somatostatin-28, and NH2-terminally extended form of somatostatin-14. RNA blotting studies show that
SSTR1
and SSTR2 are expressed at highest levels in jejunum and stomach and in cerebrum and kidney, respectively. A
SSTR1
probe hybridized to multiple DNA fragments in EcoRI digests of human and mouse DNA, indicating that
SSTR1
and SSTR2 are members of a larger family of
somatostatin
receptors. Thus, the biological effects of
somatostatin
are mediated by a family of receptors that are expressed in a tissue-specific manner.
...
PMID:Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. 134 68
Previous studies have shown that at least two subtypes of
somatostatin
(SRIF) receptors (SRIF1 and SRIF2) are expressed in mammalian cells. SRIF1 receptors have high affinity for MK 678, whereas SRIF2 receptors have no affinity for MK 678 but selectively bind peptides with structures similar to that of CGP 23996. Recently, two SRIF receptor genes have been cloned from human and mouse genomic libraries. In the present study, the pharmacological properties of these two cloned SRIF receptors, expressed in Chinese hamster ovary (CHO) cells, were investigated, to determine whether they have any similarity to the previously described SRIF1 and SRIF2 receptor subtypes. Both cloned receptors could be labeled with 125I-Tyr11-SRIF and exhibited high affinity for SRIF. The
SSTR1
receptor could also bind CGP 23996-like compounds but not MK 678. In contrast, the SSTR2 receptor was insensitive to CGP 23996-like compounds but bound MK 678 with high affinity. These findings indicate that the peptide specificities of the cloned
SSTR1
and SSTR2 receptors differ from each other. Pretreatment of CHO cells expressing the two cloned SRIF receptors with SRIF abolished high affinity agonist binding to the cloned SSTR2 receptor but not the cloned
SSTR1
receptor. Agonist binding to
SSTR1
receptors was not significantly affected by guanosine-5'-)-(3-thiotriphosphate) or pertussis toxin pretreatment, whereas agonist binding to SSTR2 receptors was inhibited by both treatments. These findings suggest that SSTR2 receptors can be regulated and they associate with pertussis toxin-sensitive guanine nucleotide-binding proteins, whereas
SSTR1
receptors do not. SRIF is a potent inhibitor of adenylyl cyclase activity in mammalian cells. However, neither the cloned SSTR2 nor
SSTR1
receptor mediated SRIF inhibition of adenylyl cyclase activity in stably transformed CHO cells or COS-1 cells transiently expressing the cloned receptors, suggesting that neither cloned receptor couples to adenylyl cyclase. The results of these studies indicate that the two cloned SRIF receptors have different pharmacological properties. The characteristics of the cloned SSTR2 receptor are similar to those of the previously described SRIF1 receptor, and the characteristics of the cloned
SSTR1
receptor are similar to those of the previously described SRIF2 receptor.
...
PMID:Pharmacological properties of two cloned somatostatin receptors. 135 50
The neuropeptide
somatostatin
(SRIF) is a neurotransmitter in the brain that exerts physiological actions including the modulation of Ca2+ and K+ conductances, neuronal cell firing, neurotransmitter release, and certain behaviors such as locomotion and cognitive functions. SRIF induces its biological effects by interacting with cell surface receptors. Recent studies have revealed that subtypes of SRIF receptors exist in the brain and other tissues. The SRIF1 receptor can be distinguished by its high affinity for the agonist MK 678, is coupled to G proteins, and mediates the stimulatory effects of SRIF on a delayed rectifier K+ current in brain neurons. Furthermore, MK 678, when applied to the nucleus accumbens, evokes locomotor activity, and SRIF1 receptors in this brain region selectively mediate the stimulation of this behavioral response to SRIF. SRIF1 receptors are unevenly distributed in the brain, with high levels in the dentate gyrus of the hippocampus, the locus coeruleus, the neostriatum, and the inner layers of the cerebral cortex. This receptor subtype has characteristics similar to the recently cloned SRIF receptor, SSTR2. A second SRIF receptor subtype has been identified in the brain and is referred to as the SRIF2 receptor. It has no affinity for MK 678, can be selectively labeled with smaller structural analogs of the peptide CGP 23996, and has characteristics similar to the recently cloned receptor subtype
SSTR1
. SRIF2 receptors are not efficiently coupled to G proteins and have a distinct but overlapping distribution in brain with SRIF1 receptors. No clear biological function has been identified for SRIF2 receptors.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Somatostatin receptors. 135 64
The tetradecapeptide
somatostatin
has been implicated as an important regulator of neuronal and neuroendocrine function in the CNS. The cellular actions of
somatostatin
are mediated by specific receptors. The genes encoding two different
somatostatin
receptors (SSTRs) have been isolated and characterized, and RNA blotting studies have shown that both
SSTR1
and SSTR2 are expressed in the brain. In order to gain a better understanding of the functions of
somatostatin
in the CNS, the distribution of
SSTR1
and SSTR2 mRNAs was determined using the technique of in situ hybridization.
SSTR1
mRNA was present throughout the mouse brain, particularly in the supra- and infragranular layers of the cortex, the amygdala, hippocampus, bed nucleus of the stria terminalis, substantia innominata, hypothalamus, pretectum, substantia nigra, parabrachial nucleus, and nucleus of the solitary tract. SSTR2 mRNA was primarily observed in the infragranular layers of the cortex, the amygdala, claustrum, endopiriform nucleus, arcuate and paraventricular nuclei of the hypothalamus, and medial habenular nucleus. Several regions of the brain reported to contain dense
somatostatin
-like immunoreactive terminal fields and receptor binding sites were devoid of both
SSTR1
and SSTR2 mRNA, suggesting the existence of additional SSTR subtypes.
...
PMID:Differential expression of somatostatin receptor subtypes in brain. 140 90
Somatostatin
(SRIF) induces its diverse physiological actions through interactions with different receptor subtypes. Multiple SRIF receptor subtypes have recently been cloned. To analyze the physical properties of receptor subtype SSTR2, two different peptide-directed antibodies were generated against SSTR2. Antibody "2e3," directed against the peptide SSCTINWPGESGAWYT (residues 191-206), corresponding to a region in the predicted third extracellular domain of mouse SSTR2, and antibody "2i4," directed against the peptide SGTEDGERSDS (residues 333-343) from the predicted cytoplasmic tail of mouse SSTR2, were developed. In Chinese hamster ovary (CHO) cells stably expressing the mouse SSTR2 gene (CHOB), the antibody 2e3 recognized specifically a protein of 93-kDa protein by immunoblotting. No specific immunoreactivity was detected by 2e3 in nontransfected CHO cells or CHO cells stably expressing vector alone or human
SSTR1
or mouse SSTR3 genes. The antibody 2i4 specifically immunoprecipitated SSTR2 solubilized from CHOB cells that could be labeled with the SSTR2-specific ligand 125I-MK-678. Furthermore, both 2e3 and 2i4 specifically immunoprecipitated 93-kDa [35S]methionine-labeled proteins from CHOB cells, indicating that they recognize the same proteins. In contrast to studies in CHOB cells, immunoblotting studies showed that 2e3 detected specifically a single 148-kDa protein from different regions of the rat brain that have previously been shown to express high levels of SSTR2 mRNA and SRIF receptors with high affinity for 125I-MK-678. In contrast, no immunoreactivity was detected in rat kidney, liver, or lung, which do not express SSTR2. No 93-kDa protein was detected specifically in the rat brain.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Immunological detection of isoforms of the somatostatin receptor subtype, SSTR2. 751 95
The signal transduction pathways of a cloned human somatostatin receptor subtype,
SSTR1
, have been investigated in CHO cells stably expressing this receptor. In
SSTR1
-expressing CHO cells, somatostatin-14 inhibits forskolin-stimulated cAMP formation in a dose-dependent manner with an ED50 of 1.0 x 10(-9) M.
Somatostatin-14
also stimulates inositol 1,4,5-trisphosphate formation in a dose-dependent manner with an ED50 of 4.0 x 10(-8) M.
Somatostatin-14
inhibitory action on adenylyl cyclase and stimulatory action on inositol 1,4,5-trisphosphate formation are both blocked by pertussis toxin, indicating that these effects of
SSTR1
are mediated by pertussis toxin-sensitive G protein(s). Antiserum against Gi alpha 3 blocked the inhibitory effects of somatostatin-14 on forskolin-stimulated adenylyl cyclase, but antiserum against Gi alpha 1/Gi alpha 2 did not, indicating that Gi alpha 3 dominantly couples
SSTR1
to adenylyl cyclase. These results demonstrate that
SSTR1
can be coupled to different signaling pathways to exert multiple biological effects, one of which is mediated by Gi alpha 3.
...
PMID:Multiple effector coupling of somatostatin receptor subtype SSTR1. 752 97
Somatostatin
(SRIF) induces its multiple biological actions by interacting with a family of receptors, referred to as
SSTR1
-SSTR5. These receptors are capable of associating with particular guanine nucleotide binding proteins to couple the receptors to distinct cellular effector systems. Therefore, G proteins have an important role in directing SRIF signalling and may provide the molecular basis for the diverse cellular actions of SRIF.
...
PMID:Somatostatin receptor activation of cellular effector systems. 753 74
Previous work from our laboratory has implicated hormone-induced plasma membrane movement (i.e., endo- and exocytosis) in water and electrolyte transport by the epithelial cells that line the ducts in the liver (i.e., cholangiocytes). To further explore the cellular mechanisms regulating ductal bile secretion, we infused
somatostatin
and/or secretin intravenously into rats 2 wk after either bile duct ligation (BDL), a procedure that induces selective proliferation of cholangiocytes, or sham surgery and measured bile flow and biliary constituents. We also determined the effect of
somatostatin
on basal and secretin-induced exocytosis by purified cholangiocytes isolated from rat liver after BDL. Finally, we studied the expression of the somatostatin receptor gene by both ribonuclease (RNase) protection and nuclear run-on assays using cDNA encoding for two subtypes of the somatostatin receptor gene (i.e.,
SSTR1
and SSTR2). In vivo,
somatostatin
infusion caused a dose-dependent bicarbonate-poor decrease (57% maximal decrease below baseline; P < 0.05) in bile flow in BDL but not in sham-operated rats; in contrast, secretin caused a dose-dependent bicarbonate-rich choleresis (228% maximal increase above baseline; P < 0.05) in BDL but not in sham-operated rats. Simultaneous or prior infusion of
somatostatin
inhibited the secretin-induced hypercholeresis in BDL rats. In vitro,
somatostatin
had no effect on basal exocytosis by cholangiocytes isolated from BDL rats; however,
somatostatin
inhitibed (88% maximal inhibition; P < 0.05) secretin-induced exocytosis by cholangiocytes in a dose-dependent fashion. In addition,
somatostatin
inhibited secretin-induced increases in levels of adenosine 3',5'-cyclic monophosphate (cAMP) in cholangiocytes isolated from BDL rats.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Somatostatin inhibits secretin-induced ductal hypercholeresis and exocytosis by cholangiocytes. 763 87
1
2
3
4
5
6
7
8
9
10
Next >>